The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Polymer therapeutics: Top 10 selling pharmaceuticals — What next?
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979
Sahay, G., Alakhova, D. Y., & Kabanov, A. V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.036 · Cited by 2,181
Believe it or not: how much can we rely on published data on potential drug targets?
Prinz, F., Schlange, T., & Asadullah, K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439-c1 · Cited by 1,888
Structure and properties of pharmacologically active polymers
Ringsdorf, H. (1975) · Journal of Polymer Science: Polymer Symposia · doi:10.1002/polc.5070510111 · Cited by 1,094 · cited 1×
“Early contributions are worthy of note; polymers as drugs (especially antibacterial agents and immunomodulators) [16–18], radioprotectants [19], polymer–drug [6,20] and polymer–protein conjugates [21,22], and block copolymermicelles [23].”
BackgroundPhase II and Phase III attrition rates 2011–2012
Arrowsmith, J., & Miller, P. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4090 · Cited by 697
Lysosomal impairment in Parkinson's disease
Dehay, B., Martinez‐Vicente, M., Caldwell, G. A., Caldwell, K. A., Yue, Z., Cookson, M. R., Klein, C., Vila, M., & Bezard, E. (2013) · Movement Disorders · doi:10.1002/mds.25462 · Cited by 340
Gaspar, R., & Duncan, R. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.06.003 · Cited by 304 · cited 2×
“EPR, is it tumour vascular permeability? Or electron paramagnetic resonance? For a legally binding regulatory process, which must avoid misunderstanding at all costs, the answer is clearly yes [2,83].”
BackgroundSelf-citation
Cited by
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization
Sun, Q., Zhou, Z., Qiu, N., & Shen, Y. (2017) · Advanced Materials · doi:10.1002/adma.201606628 · Cited by 1,058
Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities
Farjadian, F., Ghasemi, A., Gohari, O., Roointan, A., Karimi, M., & Hamblin, M. R. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0120 · Cited by 664
Polymeric nanoparticles: Promising platform for drug delivery
El-Say, K. M., & El-Sawy, H. S. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.06.052 · Cited by 608
Choi, Y. H., & Han, H.-K. (2018) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-017-0370-4 · Cited by 406
Metadata
- Authors
- Duncan, R.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 190
- Pages
- 371-380
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2038882972
- Cited by
- 161
- References
- 7
- FWCI
- 8.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.